Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

Authors: Huiying Xu, Ye Xu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

RECQL is a number of the RecQ DNA helicase family and plays an important role in maintaining genome stability. Although several studies have reported that RECQL mutations were correlated with the susceptibility to breast cancer, the effect on prognosis in breast cancer was not yet clarified. Here, we explored the association between RECQL expression level and survival in patients with breast cancer.

Methods

In the first cohort, the RECQL mRNA expression level was evaluated in 774 primary breast cancer patients using a quantitative real-time PCR assay. Then, in the second independent cohort, the level of RECQL protein expression was detected in 322 patients with breast cancer using immunohistochemistry assay. Survival curves of patients with RECQL expression were compared using the Kaplan-Meier method with log-rank test.

Results

In the first cohort of 774 breast cancer patients, the low expression level of RECQL mRNA was significantly correlated with aggressive clinicopathological characteristics, including the positive lymph node status (P = 0.026), HER2 overexpression (P < 0.001), ER negative status (P = 0.047) and high tumor grade (P = 0.041). Moreover, the low expression level of RECQL mRNA was significantly associated with poor distant recurrence-free survival (DRFS, unadjusted hazard ratio (HR): 2.77, 95% confidence interval (CI): 1.88–4.09, P < 0.001) and disease-specific survival (DSS, unadjusted HR: 3.10, 95% CI: 1.84–5.20,P < 0.001), and it remained an independent unfavorable factor for DRFS and DSS (DRFS: adjusted HR: 3.04, 95% CI: 1.89–4.87, P < 0.001; DSS: adjusted HR: 4.25, 95% CI: 2.12–8.46, P < 0.001). In the second cohort of 322 breast cancer patients, low expression of RECQL protein was also subject to poor survival in breast cancer, and it was an independent prognosis factor of poor DRFS by multivariate analysis (DRFS: adjusted HR: 2.12, 95% CI: 1.16–3.88, P = 0.015).

Conclusions

Breast cancer patients with low RECQL expression had a worse survival. The expression level of RECQL may be a potential prognosis factor for breast cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol Cell. 2015;60(4):537–46.CrossRefPubMed
3.
Chu WK, Hickson ID. RecQ helicases: multifunctional genome caretakers. Nat Rev Cancer. 2009;9(9):644–54.CrossRefPubMed
4.
5.
Seki M, Miyazawa H, Tada S, Yanagisawa J, Yamaoka T, Hoshino S, Ozawa K, Eki T, Nogami M, Okumura K, et al. Molecular cloning of cDNA encoding human DNA helicase Q1 which has homology to Escherichia coli rec Q helicase and localization of the gene at chromosome 12p12. Nucleic Acids Res. 1994;22(22):4566–73.CrossRefPubMedPubMedCentral
6.
Thangavel S, Mendoza-Maldonado R, Tissino E, Sidorova JM, Yin J, Wang W, Monnat RJ, Jr., Falaschi A, Vindigni A: Human RECQ1 and RECQ4 helicases play distinct roles in DNA replication initiation. Mol Cell Biol 2010, 30(6):1382–1396.
7.
Contreras-Levicoy J, Moreira-Ramos S, Rojas DA, Urbina F, Maldonado E. Transcription directed by human core promoters with a HomolD box sequence requires DDB1, RECQL and RNA polymerase II machinery. Gene. 2012;505(2):318–23.CrossRefPubMed
8.
LeRoy G, Carroll R, Kyin S, Seki M, Cole MD. Identification of RecQL1 as a Holliday junction processing enzyme in human cell lines. Nucleic Acids Res. 2005;33(19):6251–7.CrossRefPubMedPubMedCentral
9.
Parvathaneni S, Stortchevoi A, Sommers JA, Brosh RM Jr, Sharma S. Human RECQ1 interacts with Ku70/80 and modulates DNA end-joining of double-strand breaks. PLoS One. 2013;8(5):e62481.CrossRefPubMedPubMedCentral
10.
Sharma S, Brosh RM Jr. Human RECQ1 is a DNA damage responsive protein required for genotoxic stress resistance and suppression of sister chromatid exchanges. PLoS One. 2007;2(12):e1297.CrossRefPubMedPubMedCentral
11.
Lu X, Parvathaneni S, Hara T, Lal A, Sharma S. Replication stress induces specific enrichment of RECQ1 at common fragile sites FRA3B and FRA16D. Mol Cancer. 2013;12(1):29.CrossRefPubMedPubMedCentral
12.
Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M, Odreman F, Glatter T, Graziano S, Mendoza-Maldonado R, et al. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol. 2013;20(3):347–54.CrossRefPubMedPubMedCentral
13.
Popuri V, Croteau DL, Brosh RM, Jr., Bohr VA: RECQ1 is required for cellular resistance to replication stress and catalyzes strand exchange on stalled replication fork structures. Cell cycle (Georgetown, Tex) 2012, 11(22):4252–4265.
14.
Popuri V, Hsu J, Khadka P, Horvath K, Liu Y, Croteau DL, Bohr VA. Human RECQL1 participates in telomere maintenance. Nucleic Acids Res. 2014;42(9):5671–88.CrossRefPubMedPubMedCentral
15.
Sharma S, Stumpo DJ, Balajee AS, Bock CB, Lansdorp PM, Brosh RM Jr, Blackshear PJ. RECQL, a member of the RecQ family of DNA helicases, suppresses chromosomal instability. Mol Cell Biol. 2007;27(5):1784–94.CrossRefPubMedPubMedCentral
16.
Sun J, Wang Y, Xia Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, et al. Mutations in RECQL gene are associated with predisposition to breast Cancer. PLoS Genet. 2015;11(5):e1005228.CrossRefPubMedPubMedCentral
17.
Cybulski C, Carrot-Zhang J, Kluzniak W, Rivera B, Kashyap A, Wokolorczyk D, Giroux S, Nadaf J, Hamel N, Zhang S, et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet. 2015;47(6):643–6.CrossRefPubMed
18.
Kwong A, Shin VY, Cheuk IW, Chen J, Au CH, Ho DN, Chan TL, Ma ES, Akbari MR, Narod SA. Germline RECQL mutations in high risk Chinese breast cancer patients. Breast Cancer Res Treat. 2016;157(2):211–5.CrossRefPubMed
19.
Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(11):1720–8.CrossRef
20.
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, et al. RECQ1 A159C polymorphism is associated with overall survival of patients with resected pancreatic Cancer: a replication study in NRG oncology radiation therapy oncology group 9704. Int J Radiat Oncol Biol Phys. 2016;94(3):554–60.CrossRefPubMed
21.
Yuan H, Chen J, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(19):4365–72.CrossRef
22.
Han X, Diao L, Xu Y, Xue W, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014;25(6):1158–64.CrossRefPubMed
23.
Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. Cancer Sci. 2018;109(1):166–73.CrossRefPubMed
24.
Lao VV, Welcsh P, Luo Y, Carter KT, Dzieciatkowski S, Dintzis S, Meza J, Sarvetnick NE, Monnat RJ Jr, Loeb LA, et al. Altered RECQ helicase expression in sporadic primary colorectal cancers. Transl Oncol. 2013;6(4):458–69.CrossRefPubMedPubMedCentral
25.
Sharma S, Brosh RM Jr. Unique and important consequences of RECQ1 deficiency in mammalian cells. Cell cycle (Georgetown, Tex). 2008;7(8):989–1000.CrossRef
26.
27.
Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah T, Green AR, Ball GR, Rakha EA, Ellis IO, et al. Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers. Mol Cancer Ther. 2017;16(1):239–50.CrossRefPubMed
28.
Viziteu E, Klein B, Basbous J, Lin YL, Hirtz C, Gourzones C, Tiers L, Bruyer A, Vincent L. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia. 2017;31(10):2104–13.CrossRefPubMedPubMedCentral
29.
Matsushita Y, Yokoyama Y, Yoshida H, Osawa Y, Mizunuma M, Shigeto T, Futagami M, Imaizumi T, Mizunuma H. The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer. Journal of ovarian research. 2014;7:107.CrossRefPubMedPubMedCentral
30.
Futami K, Kumagai E, Makino H, Goto H, Takagi M, Shimamoto A, Furuichi Y. Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase. Cancer Sci. 2008;99(1):71–80.PubMed
31.
Arai A, Chano T, Futami K, Furuichi Y, Ikebuchi K, Inui T, Tameno H, Ochi Y, Shimada T, Hisa Y, et al. RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma. Cancer Res. 2011;71(13):4598–607.CrossRefPubMed
32.
Sharma S, Phatak P, Stortchevoi A, Jasin M, Larocque JR. RECQ1 plays a distinct role in cellular response to oxidative DNA damage. DNA repair. 2012;11(6):537–49.CrossRefPubMedPubMedCentral
33.
Wu Y, Brosh RM, Jr.: Distinct roles of RECQ1 in the maintenance of genomic stability. DNA repair 2010, 9(3):315–324.
Metadata
Title
Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients
Authors
Huiying Xu
Ye Xu
Tao Ouyang
Jinfeng Li
Tianfeng Wang
Zhaoqing Fan
Tie Fan
Benyao Lin
Yuntao Xie
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4585-1

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients

Research article

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study

Research article

Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Research article

Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform

Research article

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Research article

Body mass index and lung cancer risk in never smokers: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits